WHO estimates that around 235 million people currently suffer from asthma and affects people of all ages. However, about one-third of the patients are children. Asthma is a chronic (long-term) lung disease that inflames and narrows the airways, characterized by recurrent attacks of breathlessness and wheezing. Medication can control asthma.

Our R&D team has designed asthma medicines in pMDI or dry powder inhalation. For pMDI pressurized metered dose product, it can emit more than 60% of the active drug ingredient into the targeted lung area. For dry powder inhalation product, it can achieved 90% emission of the active drug ingredient into the lung.